Skip to main content

Regulatory and certification evidence

Assurance evidence before certification claims

NEUVIOR publishes assurance and certification statements only when the exact scope, date, jurisdiction, product version and supporting record can be verified.

Request current assurance contextVisit the trust centre
Current position | No generic certification badge claimsEvidence rule | Scope and date must be explicitAdoption | Local assurance remains separate

Claim standard

A badge is not a substitute for scoped evidence.

A certification, assessment or submission can support only the exact entity, system, period and scope named in its evidence.

The website must not turn an internal target, expired record or limited assessment into a general readiness claim.

01

Identify

Name the issuing body, evidence owner and source record.

02

Scope

State the product, entity, environment and jurisdiction covered.

03

Date

Show when the evidence was issued, reviewed and next requires renewal.

Assurance path

Prepare the supplier evidence, then support local adoption review.

PHARMORIS remains a non production supplier candidate. Security remediation, assurance preparation and exact head release evidence must progress before buyer readiness language is justified.

01

Supplier evidence

Document product controls, boundaries, test results and release identity.

02

Evaluation evidence

Define a paid, time limited and governed evaluation without calling it deployment.

03

Local adoption

Support the adopter’s own governance, information governance and procurement decisions.

Publication gate

Publish only the claim the evidence can carry.

If scope verification is incomplete, the status remains unknown or unpublished. Absence of proof is not upgraded into a positive certification statement.

Human decision requiredProceed only inside an evidenced and governed scope.
01

Verified

Publish the exact supported statement with source, scope and date.

Proceed
02

Partially evidenced

Narrow the wording to the confirmed portion and state the limitation.

Narrow
03

Unverified

Hold the claim until the underlying record can be checked.

No go

Classified public record

Open the classified public record

ANALYSIS + EVIDENCE BOUNDARY

Read the argument. Verify the product separately.

Published analysis can explain why governance matters. It cannot evidence security, clinical authority, certification, product readiness or local approval. Use the dated NEUVIOR records for that.

  1. AI Ethics Now / University of Warwick IATLPodcast appearance

    AI and Accountability: When Does a Suggestion Become a Decision?

    Varun Sharma joins AI Ethics Now to examine false confidence, human responsibility and the point where AI assisted suggestions become accountable decisions.

    Hear where an AI suggestion becomes a decision
  2. TechRadar ProContributed opinion

    Five questions to test whether an AI stack is truly under your control

    In TechRadar Pro, Varun Sharma sets out five tests for enterprise AI control across provenance, infrastructure, legal authority and safe exit.

    Test provenance, control and safe exit
  3. NEUVIOR InsightsNEUVIOR analysis

    From pilot theatre to financial grip: how NHS CFOs should evaluate AI in medicines optimisation

    NHS finance leaders do not need another AI pitch. They need a disciplined way to decide whether a technology can release value within the financial rules they are already being held to.

    See how a finance leader should test an AI claim
Read the governance arguments

NEUVIOR Insights and After Publication reflections are company or founder analysis. Publisher records evidence publication, not endorsement, adoption, product readiness, savings or clinical outcomes.

Make the next step useful

Bring the problem that needs a clearer decision.

Tell us what is stuck, what decision you need to make and what a better outcome would change. We will connect you to the most relevant NEUVIOR, PHARMORIS, media or investor route.

Request current assurance contextSpeak with NEUVIOR

QUESTIONS · ANSWERED DIRECTLY

The useful answers, in one place.

Browse every question
01What is NEUVIOR?

NEUVIOR is a pharmaceutical company registered in Scotland. It is building capabilities across medicines intelligence, governed technology and longer term development. PHARMORIS is its immediate product priority.

02What does NEUVIOR build today?

NEUVIOR is developing PHARMORIS, a human-governed medicines operations system in controlled, non-production development. It is intended to connect evidence, decisions, accountable work and value review. No independent TRL, deployment, customer adoption or clinical validation is claimed.

03What is PHARMORIS by NEUVIOR?

PHARMORIS is a configurable medicines operations system under controlled development. It is designed to help authorised teams progress medicine opportunities from evidence linked to its source, through an owned ActionCase, a human decision, delivery and review.

04Who founded NEUVIOR?

Varun Sharma is the Founder, CEO and CTO of NEUVIOR and leads the company and PHARMORIS product architecture.

05Where does NEUVIOR have a presence?

NEUVIOR works across Glasgow, London and Mumbai. Glasgow is the company origin and registered Scottish base. London supports commercial activity led by the founder. Mumbai supports market engagement in India and relationships across the pharmaceutical sector. These are different forms of presence. They do not imply three registered offices or regulated facilities.